It should be noted that rhIGF-1 therapy has only been approved by the US FDA to treat patients with severe primary IGF-1 deficiency or patients with GH gene deletions who have developed neutralizing antibodies to GH [21]. This evidence concerns the gene GH1 and growth delay due to insulin-like growth factor type 1 deficiency.